Brief: Crispr Therapeutics Highlights Strategic Priorities And 2024 Outlook

Crispr Therapeutics AG

08/01/2024 13:50

Jan 8 (Reuters) - CRISPR Therapeutics AG  CRSP.BN :
    * CRISPR THERAPEUTICS HIGHLIGHTS STRATEGIC PRIORITIES AND
2024
OUTLOOK
    * FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA)
ACTION
DATE OF MARCH 30, 2024, FOR CASGEVY IN TDT
    * ADDITIONAL REGULATORY SUBMISSIONS FOR CASGEVY ARE
CURRENTLY
UNDER REVIEW IN SWITZERLAND AND KINGDOM OF SAUDI ARABIA
    * SUBMISSIONS FOR CASGEVY IN CANADA PLANNED FOR FIRST HALF
OF 2024
    * CRISPR THERAPEUTICS PLANS TO INITIATE A CLINICAL TRIAL OF
CTX112
IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN FIRST HALF OF 2024
    * VIACYTE HAS ELECTED TO OPT-OUT OF COLLABORATION WITH CO
    * PER OPT-OUT TERMS, COLLABORATION ASSETS WILL NOW BE WHOLLY
OWNED
BY CO, SUBJECT TO ROYALTY ON FUTURE SALES OWED TO VIACYTE
    * OPT-OUT WILL BECOME EFFECTIVE IN EARLY FEBRUARY
    * VERTEX CONTINUES TO HAVE NON-EXCLUSIVE RIGHTS TO CERTAIN
CRISPR
THERAPEUTICS' CRISPR/CAS9 TECHNOLOGY

Source text for Eikon:  ID:nGNX8Q4cHT 
Further company coverage:  CRSP.BN 

 ((Reuters.Briefs@thomsonreuters.com;))